RxDoctor Payments Data

Renee Holley, NP

Family · Fort Wayne, INNPI 1932383254

Payments from drug & device makers

$10,804in general payments, 2019–2025

Across 602 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Sanofi$801
  • Grifols USA, LLC$786
  • AbbVie$786
  • Optinose US, Inc.$459
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$460%
  • Food & beverage$10,67999%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,804 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$25,903
Medicare patients
91
Services billed
1,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter157$120,333
Breo ElliptaFluticasone/Vilanterol105$54,779
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$47,628
Advair HfaFluticasone Propion/Salmeterol40$20,028
SymbicortBudesonide/Formoterol Fumarate43$18,194
Spiriva RespimatTiotropium Bromide20$14,554
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$10,658
Emgality PenGalcanezumab-Gnlm11$7,960
Albuterol Sulfate39$6,150
Azelastine Hcl140$4,580
Albuterol Sulfate HfaAlbuterol Sulfate208$4,562
Famotidine317$4,352
Fluticasone Propionate HfaFluticasone Propionate15$4,333
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$4,214
Incruse ElliptaUmeclidinium Bromide12$4,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,884$179,290274 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,871$65,82298 claims
Boehringer IngelheimSpiriva Respimat$117$14,55420 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$422$6,15039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →